BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Biotech Bay

  DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

  DURECT Corporation announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually, February 13-14, 2024.

  February 7, 2024

   · 

  4 min read
• Drug Development

  Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

  Tenax Therapeutics, Inc. announced that the first patient has enrolled in the Company’s Phase 3 LEVEL Study.

  February 7, 2024

   · 

  6 min read
• Deals

  Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

  Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

  February 7, 2024

   · 

  4 min read